Acadia Stock Jumps on Positive Dementia-Related Psychosis Drug Data

An Acadia Pharmaceuticals drug that’s already approved for psychosis associated with Parkinson’s disease could soon be heading to an FDA review to expand the use of the drug to dementia patients. On Monday, Acadia (NASDAQ: ACAD) reported that its drug, pimavanserin, met the goal of delaying relapse of psychosis in dementia patients compared to a […]

Click to view original post